Parkinson's disease

French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics

Retrieved on: 
Mittwoch, April 3, 2024
Parkinson's disease, Ecosystem, Psychiatry, Health, Eisai, Loxapine, Dependent territory, CNX, Patient, Global Health, Neurology, Marketing, Therapy, Anxiety, Pharmaceutical industry

TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S.

Key Points: 
  • TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S.
  • entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited.
  • Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2024.
  • acquired the rights to both treatments in the Territory in July 2002 and has been marketing them since.

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Retrieved on: 
Donnerstag, Mai 9, 2024
HIV/AIDS, Nephrology, FDA, Parkinson's disease, New chemical entity, CTD, Woman, Pulmonary hypertension, Blood, Food, Imatinib, NME, Connective tissue disease, PAH, Partnership, IND, Cardiology, Disease, Therapy, Patent, Ventricular septal defect, HIV, Clinical trial, HERG, Division, Investigational New Drug, Pharmaceutical industry

BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration (FDA) for IkT-001Pro (“Pro”) as a candidate treatment for Pulmonary Arterial Hypertension (PAH). Following review of the final meeting minutes, Inhibikase is preparing the Investigational New Drug (IND) application.

Key Points: 
  • Following review of the final meeting minutes, Inhibikase is preparing the Investigational New Drug (IND) application.
  • If approved, IkT-001Pro could be a branded product with all the value drivers of a novel treatment for an indication of high unmet medical need.
  • In parallel, the Company has initiated discussions with potential strategic partners in order to advance the development of Pro for Pulmonary Arterial Hypertension.
  • Pulmonary Arterial Hypertension is a rare disease of the pulmonary microvasculature.

FDA Grants Orphan Drug Designation to Biompharma’s Bi104, a microbiome-modifying biologic, for the treatment of Angelman Syndrome

Retrieved on: 
Mittwoch, Mai 8, 2024
FDA, Speech, Hope, Angelman syndrome, Food, Neuroinflammation, Parkinson's disease, Neurodevelopmental disorder, Epilepsy, Research, Spectrum, Seizure, Alzheimer's disease, Disease, Therapy, Patient, DSM-IV codes, Intellectual disability, Multiple sclerosis, Pharmaceutical industry

Sarasota, Florida, May 08, 2024 (GLOBE NEWSWIRE) -- BIOM Pharmaceutical Corporation is thrilled to announce that Bi104, its innovative drug product, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of Angelman syndrome (AS).

Key Points: 
  • Sarasota, Florida, May 08, 2024 (GLOBE NEWSWIRE) -- BIOM Pharmaceutical Corporation is thrilled to announce that Bi104, its innovative drug product, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of Angelman syndrome (AS).
  • Angelman Syndrome (AS) is a rare neurodevelopmental disorder characterized by developmental delay, intellectual disability, speech impairment, and motor abnormalities.
  • Currently, there is no specific treatment approved for preventing or controlling AS.
  • “Procuring orphan designation for Bi104 is a major milestone for us and validates our technology and formulation to initiate a clinical program.

BPGbio Brings Late Clinical Stage Rare Disease and Oncology Assets to US and EU Pharma Partnering Summits

Retrieved on: 
Dienstag, Mai 7, 2024
Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Neurology, FDA, Health, Breast cancer, Brain, Q10, HPC, Parkinson's disease, Carcinoma, Liver disease, Oak Ridge National Laboratory, State, Pancreatic cancer, Doctor of Philosophy, Tumor microenvironment, GBM, Epidermolysis bullosa, SCC, Therapy, Patient, Sarcopenia, Glioblastoma, Biomarker, Drug discovery, Orphan drug, EB, TME, Pharmaceutical industry

BPGbio’s executives, including Daniel Elliott , Board Member and Chief Commercial Advisor, plan to share details of the company’s commercial ready assets.

Key Points: 
  • BPGbio’s executives, including Daniel Elliott , Board Member and Chief Commercial Advisor, plan to share details of the company’s commercial ready assets.
  • BPM31510 acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.
  • BPGbio is also exploring a late stage trial with BPM31510-IV/oral for primary coenzyme Q10 deficiency , an ultra-rare, potentially life threatening disease that affects the brain, muscles, and kidneys in afflicted patients.
  • This platform identifies targets, biomarkers, and drugs and assists the development team through both the development and clinical trial stages.

Husson University Names First-Ever Geneva Allen Professor

Retrieved on: 
Dienstag, Mai 7, 2024
Education, Husson University, University, Parkinson's disease, Pennsylvania State University, Health, Gait, Humanities, Publishing, Communication, Research, University of Liverpool, Science, Medicine, College, Loughborough University, Faculty, Multimedia, Husson, Louisiana State University, Student, Nursing

BANGOR, Maine, May 7, 2024 /PRNewswire-PRWeb/ -- Husson University has named Ben Sidaway as the first-ever Geneva S. Allen '49 Professor in Health Sciences.

Key Points: 
  • BANGOR, Maine, May 7, 2024 /PRNewswire-PRWeb/ -- Husson University has named Ben Sidaway as the first-ever Geneva S. Allen '49 Professor in Health Sciences.
  • "It's a tremendous honor to be the first Geneva Allen Endowed Professor in the College of Health and Pharmacy.
  • The professorship is named for the late Geneva S. Allen, who graduated from Husson University in 1949 and again in 1995.
  • "We are so grateful that Geneva S. Allen chose to support Husson University with an unrestricted estate gift that has been used to create this endowed professorship as well as create a fund to honor outstanding Husson faculty and staff.

2024 World Brain Day Dedicated to Brain Health and Prevention

Retrieved on: 
Dienstag, Mai 7, 2024
Public, World government, Myenteric plexus, Mayo Clinic, Stroke, Parkinson's disease, WHO, Social media, Neurological disorder, World Health Organization, Policy, Risk, WBD, Guest, Health care, MD, Life, Alzheimer's disease, Culture, Exercise, Smoking cessation, Encephalitis, Society, Diet, Meningitis, DSM-IV codes, Movement, Epilepsy, Multiple sclerosis, Dementia, Sleep, WFN

LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.
  • "This World Brain Day is a chance for us to unite and advocate for our present and future," says Prof. Tissa Wijeratne, World Brain Day Co-Chair.
  • "As we approach World Brain Day 2024, let's come together to support brain health and prevention.
  • Mark your calendars for July 22—a day dedicated to celebrating brain health and promoting prevention.

2024 World Brain Day Dedicated to Brain Health and Prevention

Retrieved on: 
Dienstag, Mai 7, 2024
Public, World government, Myenteric plexus, Mayo Clinic, Stroke, Parkinson's disease, WHO, Social media, Neurological disorder, World Health Organization, Policy, Risk, WBD, Guest, Health care, MD, Life, Alzheimer's disease, Culture, Exercise, Smoking cessation, Encephalitis, Society, Diet, Meningitis, DSM-IV codes, Movement, Epilepsy, Multiple sclerosis, Dementia, Sleep, WFN

LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.
  • "This World Brain Day is a chance for us to unite and advocate for our present and future," says Prof. Tissa Wijeratne, World Brain Day Co-Chair.
  • "As we approach World Brain Day 2024, let's come together to support brain health and prevention.
  • Mark your calendars for July 22—a day dedicated to celebrating brain health and promoting prevention.

A Holistic Approach to Parkinson's Disease Endpoint Data Collection: Efficacy, Safety and Quality of Life, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Dienstag, April 30, 2024
Brain, Parkinson's disease, Safety, QOL, Data science, MD, Doctor of Philosophy, American Opportunity Tax Credit, Diary, QT, Pros, MPH, Medicine, PD, Quality of life, Dysautonomia

TORONTO, April 30, 2024 /PRNewswire-PRWeb/ -- In this webinar, the expert speakers will comprehensively explore Parkinson's disease endpoint data collection, where they will delve into the crucial elements of efficacy, safety and quality of life. The webinar will highlight the revolutionary Opal wearable solution and its important role in providing quantitative gait assessments, thus offering a better understanding of disease progression.

Key Points: 
  • TORONTO, April 30, 2024 /PRNewswire-PRWeb/ -- In this webinar, the expert speakers will comprehensively explore Parkinson's disease endpoint data collection, where they will delve into the crucial elements of efficacy, safety and quality of life.
  • The webinar will highlight the revolutionary Opal wearable solution and its important role in providing quantitative gait assessments, thus offering a better understanding of disease progression.
  • These circuits represent crucial targets for assessing patient eligibility, safety and therapeutic efficacy in the development of disease-modifying therapies.
  • Register for this webinar to learn about the complexities of Parkinson's disease endpoint data collection and obtain invaluable insights for improving patient outcomes and advancing therapeutic interventions.

Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline

Retrieved on: 
Donnerstag, April 25, 2024
Doctor of Philosophy, Parkinson's disease, Protein, Central nervous system disease, ALS, GV (company), MD, Research, CNS, Therapy, GPR6, Frontotemporal dementia, Patient, MPP, Central nervous system, KCNK13, MBA, Drug development, Drug discovery, Series, Pharmaceutical industry

BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised bringing the total Series B-1 raise to $98 million. The financing is led by Agent Capital, Bioluminescence Ventures, and Double Point Ventures, with participation from new investors MQB Partners and LifeRock Ventures and existing investors Gates Frontier, GV (Google Ventures), and Lightstone Ventures. In conjunction with the financing, Campbell Murray, MD, MPP, MBA, Partner at Agent Capital and Kouki Harasaki, Ph.D., MBA, Founder and Managing Partner at Bioluminescence Ventures, have joined the Cerevance Board of Directors.

Key Points: 
  • “The support from new and existing investors underscores the ongoing advancements made by Cerevance,” said Craig Thompson, chief executive officer of Cerevance.
  • “The remarkable NETSseq platform is accelerating innovation and tangible clinical benefits are emerging from Cerevance's precision approach to CNS therapies.
  • Cerevance is advancing a robust and expanding pipeline of clinical and preclinical programs, including the lead program, CVN424, a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6).
  • The company’s earlier-stage pipeline includes multiple first-in-class opportunities in preclinical development, including programs focused on disease modification in Parkinson’s disease and Alzheimer’s disease.

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Retrieved on: 
Donnerstag, April 18, 2024
FDA, Bangladesh Technical Education Board, Parkinson's disease, Safety, NIH, Pulmonary hypertension, Food, Imatinib, NINDS, PAH, DSM-IV codes, Pathology, Mesylate, Letter, Disease, Therapy, Patent, Multiple system atrophy, Patient, Biomarker, PD, Pharmaceutical industry

BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders.

Key Points: 
  • BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders.
  • Dear Fellow Shareholders of Inhibikase Therapeutics:
    2024 has been off to a productive start for Inhibikase.
  • Our 201 Trial is approximately 75% enrolled, with the last patient anticipated to enter the trial in June.
  • We have only 30 patients left to enroll as of April 18, 2024, and we expect to complete enrollment in approximately mid-June.